Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Hims & Hers Health (NYSE: HIMS) is a relatively young company addressing age-old healthcare challenges by offering ...

If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

In clinical trials, tirzepatide (the active ingredient in both Mounjaro and ... profits (based on analyst estimates), Eli ...

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...

The FDA is about to make it a lot harder to get cheap weight-loss drugs Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a life ...

In clinical trials, tirzepatide (the active ingredient in both ... estimates), Eli Lilly can still be an excellent long-term buy given the potential it has. This is an unstoppable growth stock ...